Regeneron Pharmaceuticals Inc
XBER:RGO

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
XBER:RGO
Watchlist
Price: 128.94 EUR 0.71% Market Closed
Market Cap: 13.9B EUR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

RGO Price Targets Summary
Regeneron Pharmaceuticals Inc

Wall Street analysts forecast RGO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RGO is 645.69 EUR with a low forecast of 438.09 EUR and a high forecast of 915.4 EUR.

RGO Lowest Forecast
Wall Street Target
438.09 EUR
240% Upside
RGO Average Forecast
Wall Street Target
645.69 EUR
401% Upside
RGO Highest Forecast
Wall Street Target
915.4 EUR
610% Upside
Lowest
Price Target
438.09 EUR
240% Upside
Average
Price Target
645.69 EUR
401% Upside
Highest
Price Target
915.4 EUR
610% Upside
Regeneron Pharmaceuticals Inc Competitors:
Price Targets
EXAS
Exact Sciences Corp
45% Upside
H
145020
Hugel Inc
35% Upside
300294
China Resources Boya Bio pharmaceutical Group Co Ltd
25% Upside
VLA
Valneva SE
121% Upside
EXAS
Exact Sciences Corp
45% Upside
H
145020
Hugel Inc
35% Upside
300294
China Resources Boya Bio pharmaceutical Group Co Ltd
25% Upside
VLA
Valneva SE
121% Upside
I
086890
Isu Abxis Co Ltd
82% Upside
ACAD
ACADIA Pharmaceuticals Inc
25% Upside
688520
Sinocelltech Group Ltd
27% Downside
ADMA
ADMA Biologics Inc
67% Upside

Revenue
Forecast

Revenue Estimate
Regeneron Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's revenue is 14%. The projected CAGR for the next 3 years is 4%.

14%
Past Growth
4%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Regeneron Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's operating income is 16%. The projected CAGR for the next 3 years is 11%.

16%
Past Growth
11%
Estimated Growth
Estimates Accuracy
-15%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Regeneron Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's net income is 22%. The projected CAGR for the next 3 years is 7%.

22%
Past Growth
7%
Estimated Growth
Estimates Accuracy
-11%
Average Miss
What are analyst estimates?

See Also

Summary
RGO intrinsic value, competitors valuation, and company profile.
DCF Valuation
RGO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RGO stock valuation using valuation multiples.
Wall Street Estimates
RGO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RGO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RGO's stock price target?
Price Target
645.69 EUR

According to Wall Street analysts, the average 1-year price target for RGO is 645.69 EUR with a low forecast of 438.09 EUR and a high forecast of 915.4 EUR.

What is Regeneron Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
4%

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's revenue is 14%. The projected CAGR for the next 3 years is 4%.

What is Regeneron Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
11%

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's operating income is 16%. The projected CAGR for the next 3 years is 11%.

What is Regeneron Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
7%

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's net income is 22%. The projected CAGR for the next 3 years is 7%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 270,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.